The global pharmacogenetic testing in psychiatry depression market is experiencing notable growth as mental health professionals increasingly recognize the value of personalized medicine in treating depression. Pharmacogenetic testing enables clinicians to tailor antidepressant therapies based on individual genetic profiles, improving treatment efficacy and minimizing adverse drug reactions. The rising prevalence of depression worldwide, coupled with the increasing emphasis on precision medicine, is driving demand for pharmacogenetic testing. Advances in genetic research and technology have made testing more accessible and cost-effective, further fueling market expansion. Moreover, collaborations between pharmaceutical companies and genetic testing providers are enhancing the development of targeted therapies, which are expected to improve patient outcomes. However, challenges such as varying regulatory landscapes, limited reimbursement policies, and the need for clinician education on the utility of pharmacogenetic testing may hinder market growth. Overall, the market is poised for continued expansion as awareness of the benefits of personalized treatment in psychiatry grows.
Global Pharmacogenetics Testing in Psychiatry/Depression Market is valued at USD 1.22 billion in 2023 and is expected to reach USD 2.66 billion by 2031, with a growing CAGR of 4.71% during the forecast period 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/reports/global-pharmacogenetic-testing-in-psychiatry-depression-market
Below are the Top Pharmacogenetic Testing in Psychiatry/Depression Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Myriad Genetics, Inc.
|
Myriad Genetics, Inc. is a pioneering company in the field of molecular diagnostics and personalized medicine. The company specializes in genetic testing for various conditions, including psychiatric disorders. Myriad offers pharmacogenetic tests that assess how an individual's genetic makeup influences their response to psychiatric medications, helping clinicians make informed treatment decisions for patients with depression. Their tests aim to optimize medication efficacy and minimize adverse effects, aligning with the growing trend toward personalized healthcare solutions in psychiatry.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In July 2020, Myriad Genetics, Inc. announced the launch of a home collection kit for patients for the GeneSight Psychotropic Test. The test will help the doctors understand the impact of antidepressants and other drugs related to the same on the genetic makeup of the patient. This will help them administer drugs that will be suitable for their patients improving the outcomes. This will help in the growth of the market in fore coming years.
|
|
2.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific Inc. is a global leader in scientific research and diagnostics, providing a wide range of products and services, including advanced genetic testing solutions. The company offers innovative tools for pharmacogenetic testing that enable healthcare providers to analyze genetic variations affecting patient responses to antidepressants. Thermo Fisher's commitment to advancing personalized medicine through its extensive portfolio of genomic technologies plays a crucial role in the evolving landscape of psychiatric treatment, particularly in the management of depression.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In May 2019, Thermo Fisher Scientific Inc. signed an agreement on acquiring a drug manufacturing site from GlaxoSmithKline plc, situated in Cork, Ireland. This will help in expanding the manufacturing active pharmaceutical ingredients that are complex in nature. These APIs can prove too helpful in treating disorder such as depression. The increase in developmental as well as commercial capabilities will help in the growth of the market in the coming years.
|
|
3.
|
STADA Arzneimittel AG
|
STADA Arzneimittel AG is a German pharmaceutical company that focuses on the development and marketing of generic and specialty pharmaceuticals, including those for psychiatric conditions. While primarily known for its medications, STADA is also involved in the pharmacogenetic testing market, aiming to enhance treatment outcomes for patients with depression. The company's initiatives in personalized medicine emphasize the importance of tailoring therapies based on individual genetic profiles, which aligns with the growing demand for precision medicine in psychiatry.
|
|
Middle East and Africa, Asia-Pacific, and Europe
|
In March 2017, STADA Arzneimittel AG reported a dosage-response relationship of antidepressants in the treatment of depression. The news article stated that SSRIs, Selective serotonin reuptake inhibitors, has become a primary choice for the treatment of depression. It stated that a flat dosage-response relationship has been established for SSRIs. The DNA testing kits for antidepressants by STADA Diagnostika will be able to further help in validating the effect of antidepressants and their efficacy and has helped drive the growth of the market.
|
|
4.
|
Sonic Healthcare
|
Sonic Healthcare is a prominent global healthcare company providing laboratory and radiology services, including genetic testing and diagnostics. The company offers pharmacogenetic testing services that help clinicians understand how genetic factors influence patient responses to psychiatric medications. Sonic Healthcare's extensive network of laboratories ensures efficient testing and results delivery, facilitating timely treatment decisions for patients with depression. Their focus on personalized medicine aligns with the increasing emphasis on tailored healthcare solutions in psychiatry.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In July 2018, Sonic Genetics, a division of Sonic Healthcare announced the implementation of pharmacogenetics decision support software for its lab testing services from translational software in Australia. This will help in guiding clinical decision-making and help the company to grow in the coming years.
|
|
5.
|
Illumina,Inc.
|
Illumina, Inc. is a leading developer of next-generation sequencing technology and genomic solutions that drive advancements in personalized medicine. The company provides a comprehensive range of tools and platforms for genetic testing, including pharmacogenetic testing aimed at optimizing psychiatric treatment. Illumina's innovative technologies enable researchers and healthcare providers to analyze genetic variations associated with medication responses, paving the way for more effective treatment strategies for depression. With a strong commitment to improving patient outcomes through genomics, Illumina is at the forefront of the pharmacogenetics market in psychiatry.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In September 2019, Illumina, Inc. went under collaboration with the Broad Institute of MIT and Harvard for the development of secondary genomic software and algorithms. The company is investing for such innovation in order to deliver best- in –class open source software for common genomic testing methods. This initiative boosted the clinical adoption of sequencing methods by decreasing the overall cost and time of genome analysis.
|
Conclusion
The global pharmacogenetic testing in psychiatry depression market is positioned for significant growth, driven by the increasing recognition of personalized medicine's role in effectively treating depression. As healthcare professionals prioritize tailored treatment approaches that consider individual genetic variations, pharmacogenetic testing emerges as a critical tool in enhancing therapeutic outcomes and minimizing adverse effects. The expanding prevalence of depression, coupled with advancements in genetic testing technology and collaborative efforts between pharmaceutical and testing companies, is expected to propel market development.
